- $24.39bn
- $20.57bn
- $5.14bn
Incyte up after blood cancer therapy meets main goal in late-stage trial
Incyte's blood cancer therapy meets main goal in late-stage trial (updated)
Incyte's blood cancer therapy meets main goal in late-stage trial
U.S. RESEARCH ROUNDUP-Incyte, ServiceNow, Spire Global
Brief: Incyte Announces European Commission Approval Of Minjuvi (Tafasitamab)
U.S. STOCKS ON THE MOVE-Robinhood Markets, Cannabis stocks, Hyatt Hotels
Incyte up after European Commission expands use of cancer drug
U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart
Incyte down after investors set high expectations for blood cancer therapy trial
Buzz Us Stocks On The Move: Tesla, Warner Bros Discovery, Netflix
U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix
Incyte rises after antibody therapy shows potential in rare blood cancers
Brief: Incyte Appoints Richard Hoffman As Executive Vice President And General Counsel
U.S. RESEARCH ROUNDUP- Amgen, Crowdstrike, Micron Technology
Brief: Prelude, Incyte Sign Exclusive Option Deal To Advance JAK2V617F JH2 Inhibitors For Cancer Therapy
U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx SE, Cardinal Health Inc
U.S. RESEARCH ROUNDUP-ATI, GoDaddy, Lyft
Incyte lifts forecast for key drug Jakafi, but pipeline rejig drags shares (updated)
Incyte boosts annual sales forecast of blood cancer drug after strong quarter